Dr Reddys Laboratories Ltd (RDY) SEC filings

RDYNYSEPharmaceutical PreparationsFiscal year ends March 31

Financials through fiscal 2026, year ended Mar 31, 2026Score 7/30

$14.74+0.01 (+0.07%)

Close on Nov 13, 2026Market cap $12.30BP/E 26.9Yield 0.58%

SEC filings

40 of Dr Reddys Laboratories's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	6-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Current report	6-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Current report	6-K	Nov 4, 2026	Nov 4, 2026	SEC EDGAR
Current report	6-K	Oct 29, 2026	Oct 29, 2026	SEC EDGAR
Current report	6-K	Oct 28, 2026	Oct 29, 2026	SEC EDGAR
Current report	6-K	Oct 24, 2026	Oct 26, 2026	SEC EDGAR
Current report	6-K	Oct 24, 2026	Oct 26, 2026	SEC EDGAR
Current report	6-K	Oct 23, 2026	Oct 23, 2026	SEC EDGAR
Current report	6-K	Oct 23, 2026	Oct 23, 2026	SEC EDGAR
Current report	6-K	Oct 23, 2026	Oct 23, 2026	SEC EDGAR
Current report	6-K	Oct 23, 2026	Oct 23, 2026	SEC EDGAR
Current report	6-K	Oct 21, 2026	Oct 21, 2026	SEC EDGAR
Current report	6-K	Oct 14, 2026	Oct 14, 2026	SEC EDGAR
Current report	6-K	Oct 8, 2026	Oct 8, 2026	SEC EDGAR
Current report	6-K	Oct 7, 2026	Oct 7, 2026	SEC EDGAR
Current report	6-K	Oct 3, 2026	Oct 5, 2026	SEC EDGAR
Current report	6-K	Sep 22, 2026	Sep 22, 2026	SEC EDGAR
Current report	6-K	Sep 21, 2026	Sep 21, 2026	SEC EDGAR
Current report	6-K	Sep 18, 2026	Sep 18, 2026	SEC EDGAR
Current report	6-K	Sep 11, 2026	Sep 14, 2026	SEC EDGAR
Current report	6-K	Sep 10, 2026	Sep 10, 2026	SEC EDGAR
Current report	6-K	Sep 10, 2026	Sep 10, 2026	SEC EDGAR
Current report	6-K	Aug 26, 2026	Aug 26, 2026	SEC EDGAR
Current report	6-K	Aug 14, 2026	Aug 17, 2026	SEC EDGAR
Current report	6-K	Aug 14, 2026	Aug 17, 2026	SEC EDGAR
Current report	6-K	Aug 13, 2026	Aug 13, 2026	SEC EDGAR
Current report	6-K	Aug 7, 2026	Aug 10, 2026	SEC EDGAR
Current report	6-K	Aug 1, 2026	Aug 3, 2026	SEC EDGAR
Current report	6-K	Jul 29, 2026	Jul 29, 2026	SEC EDGAR
Current report	6-K	Jul 28, 2026	Jul 29, 2026	SEC EDGAR
Current report	6-K	Jul 23, 2026	Jul 23, 2026	SEC EDGAR
Current report	6-K	Jul 23, 2026	Jul 23, 2026	SEC EDGAR
Current report	6-K	Jul 23, 2026	Jul 23, 2026	SEC EDGAR
Current report	6-K	Jul 23, 2026	Jul 23, 2026	SEC EDGAR
Current report	6-K	Jul 23, 2026	Jul 23, 2026	SEC EDGAR
Current report	6-K	Jul 22, 2026	Jul 22, 2026	SEC EDGAR
Current report	6-K	Jul 22, 2026	Jul 22, 2026	SEC EDGAR
Current report	6-K	Jul 22, 2026	Jul 22, 2026	SEC EDGAR
Current report	6-K	Jul 22, 2026	Jul 22, 2026	SEC EDGAR
Current report	6-K	Jul 22, 2026	Jul 22, 2026	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Dr Reddys Laboratories's annual and quarterly filings with the SEC
Per-share figures adjusted for the 5-for-1 split on Jun 6, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RDY.

Compare: RDY vs NVO · RDY vs LLY · RDY vs MRK · RDY vs JNJ · RDY vs ABBV

Revenue growth3.2% · median 9.1%

Gross margin52.8% · median 71.6%

Net margin12.8% · median 13.0%

Company	Revenue	Growth
RDY	₹335.93B	+3.2%
JNJ	$99.34B	+7.8%
LLY	$86.46B	+45.5%
MRK	$67.38B	+4.9%
ABBV	$64.39B	+10.4%
NVO	–	–

Company

Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: March 31
Held by institutions: 15.1%
Auditor: Ernst & Young Associates LLP
SEC CIK: 1135951

Advertisement
300 × 250

See a number that looks wrong?